Presented by Global DDI Solutions in collaboration with Academic Medical Education, the DDI of the Month podcast brings you the latest updates on drug-drug interactions.
Each month, a new paper will be selected and the author invited to discuss their findings and explore how this can optimize DDI management and patient care going forward.
Host: Dr. David Burger - Professor of Clinical Pharmacy at the Radboud University in Nijmegen, the Netherlands.
He is an Executive Editor of BJCP and serves on the editorial boards of TDM, JAIDS, JAC, and Antiviral Therapy. Since 1997 he has been leading a research group focussing on clinical pharmacology of antimicrobial agents with emphasis on HIV, TB, fungal infections, and hepatitis.
Episode 10: An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib
In this 10th edition of DDI of the Month, host Prof. dr. David Burger welcomes dr. Joe Piscitelli from Pfizer, USA, for an in-depth discussion on the DDI profile of encorafenib. Encorafenib is a potent and selective small-molecule inhibitor of BRAF V600-mutant kinase, and approved for various malignancies, including non-small cell lung cancer. Based on in vitro research there was uncertainty about the DDI potential of encorafenib as a precipitant drug. Piscitelli et al. conducted a so-c...
19 Dec 2025
Episode 9: Decoding P-glycoprotein Interactions: Inhibitors, Inducers, and Clinical Relevance
In this ninth edition of DDI of the Month, host Prof. dr. David Burger welcomes two leading experts from Switzerland, Dr Claire Coumau and Dr Chantal Csajka, for an in-depth discussion on P-glycoprotein (P-gp)–mediated drug–drug interactions. The episode is centered around their recent publication in Clinical Pharmacokinetics: “A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs.”...
2 Jul 2025
Episode 8: Metamizole Meets Quetiapine: A Metabolic Interaction
Dr. Arnim Gaebler and Dr. Michael Paulzen discuss their research on the interaction between metamizole and quetiapine, revealing the clinical impact of this polypharmacy combination in this interview episode.
19 Feb 2025
Episode 7: Pharmacokinetics and Green Tea: The Catechin Connection
In the seventh episode, Prof. Dr. David Burger discusses with Nicki Kyriacou the review article: “Green tea catechins as perpetrators of drug pharmacokinetic interactions”. You might think: “Green tea?– I drink it all the time! “But is it really that innocent? Tune in now as we explore how catechins-compounds found in green tea, like (-)-epigallocatechin-3-gallate – can impact drug pharmacokinetics. These compounds can alter drug solubility, transporter activity, and metabolism, potenti...
9 Jan 2025
Episode 6: The Role of P-gp and the Impact on Clinical Outcomes | Leonie Bogaard
In this episode of the DDI of the Month podcast, Dr. David Burger dives into a critical topic: P-glycoprotein (P-gp)-mediated Drug-Drug Interactions with Dr. Leonie Bogaard. Join us as we explore the role of P-gp, a key transporter involved in drug absorption and elimination, and its impact on clinical outcomes.In this episode, we discuss:• How P-gp modulation affects systemic drug exposure.• The challenges in managing DDIs due to overlap with enzymes like CYP3A4.•&n...
25 Oct 2024
Episode 5: Enhancing Patient Safety
In our latest episode, we dive into an important study by Dr. Massimo and Dr. Gianluca which examins the agreement between different drug interaction checkers (ICs) when evaluating interactions involving widely used proton pump inhibitors (PPIs). PPIs are frequently prescribed for treating acid-related conditions and preventing medication-induced ulcers, especially in older patients with multimorbidity and polypharmacy. These interactions are often complex, involving increased gastric pH...
25 Sept 2024
AI’s potential for improving CDSS
The fourth episode will delve into the use of artificial intelligence (AI) to optimize medication alerts generated by clinical decision support systems (CDSSs). David Burger will discuss the review findings and future opportunities with Jetske Graafsma and Dr. Patricia van den Bemt. Medication safety is crucial, and preventing adverse drug events (ADEs) is a key aspect. Clinical decision support systems (CDSSs) in electronic health records help reduce the risk of ADEs by generating alert...
18 Jun 2024
Episode 3: Real-World Clinical DDI Cases
In the third podcast, Dr. Burger discusses the added value of reporting outcomes of real-world cases in patients with HIV caused by drug-drug interactions (DDIs) with Dr. Ambrosioni and Dr. Molto.
Several databases are available for DDI management, with discrepancies often occurring between the databases. The differences may be caused by extrapolations from studied interactions to predict the DDI potential for unknown drug combinations. The relevance of the unstudied DDIs is often unknown.
Reporting the outcomes of real-world cases can determine the relevance of DDIs. The article discusses real-world cases between antiretrovirals (ARVs) and comedications reported on www.clinicalcasesDDIs.com (https://www.clinicalcasesddis.com/). Twenty percent of the reported cases involve over-the-counter drugs, which are often not recorded in patient files.
The following topics will be discussed during the podcast:
- the challenges of DDI management of ARVs with comedications;
- the added value of reporting outcomes of real-world cases; and
- the underestimated risks of over-the-counter (OTC) drug use.
Listen to the podcast for all the tips and take-home messages!
Read the full article here: https://link.springer.com/article/10.1007/s40121-024-00935-0 (https://link.springer.com/article/10.1007/s40121-024-00935-0)
18 Jun 2024
Episode 3: Real-World Clinical DDI Cases | Juan Ambrosioni & José Moltó
In the third podcast, Dr. Burger discusses the added value of reporting outcomes of real-world cases in patients with HIV caused by drug-drug interactions (DDIs) with Dr. Ambrosioni and Dr. Molto.
Several databases are available for DDI management, with discrepancies often occurring between the databases. The differences may be caused by extrapolations from studied interactions to predict the DDI potential for unknown drug combinations. The relevance of the unstudied DDIs is often unknown.
Reporting the outcomes of real-world cases can determine the relevance of DDIs. The article discusses real-world cases between antiretrovirals (ARVs) and comedications reported on www.clinicalcasesDDIs.com (https://www.clinicalcasesddis.com/). Twenty percent of the reported cases involve over-the-counter drugs, which are often not recorded in patient files.
The following topics will be discussed during the podcast:
- the challenges of DDI management of ARVs with comedications;
- the added value of reporting outcomes of real-world cases; and
- the underestimated risks of over-the-counter (OTC) drug use.
Listen to the podcast for all the tips and take-home messages!
Read the full article here: https://link.springer.com/article/10.1007/s40121-024-00935-0 (https://link.springer.com/article/10.1007/s40121-024-00935-0)
16 May 2024
Episode 2: Colchicine | Daniel Malone & Ainhoa Gomez-Lumbreras
In the second episode of this podcast series, Dr. Malone, Dr. Gómez-Lumbreras, and Dr. Burger will discuss the drug-drug interaction potential of colchicine, which may be underestimated.
Dr. Malone’s research group did a study on real-world data on the interaction potential of colchicine. Colchicine concentration can be increased by CYP3A4 inhibitors, which may lead to toxicity and adverse events. Adverse events cases reported between 2004 and 2020 were studied for the involvement of colchicine in DDIs. In 66% of 787 studied reports, colchicine was identified as a concomitant drug. This indicates that the reporter did not think colchicine was the cause of the adverse events mentioned in the reports.
Could colchicine possibly play a bigger role in DDIs than currently thought?
Are there any safety concerns of colchicine use combined with strong CYP3A4 inhibitors?
And what practical guidance is needed for the safe use of colchicine in combination with other medicines?
Listen to the second episode of DDI of the Month to find out!
16 May 2024
Episode 2: Daniel Malone & Ainhoa Gomez-Lumbreras
In the second episode of this podcast series, Dr. Malone, Dr. Gómez-Lumbreras, and Dr. Burger will discuss the drug-drug interaction potential of colchicine, which may be underestimated.
Dr. Malone’s research group did a study on real-world data on the interaction potential of colchicine. Colchicine concentration can be increased by CYP3A4 inhibitors, which may lead to toxicity and adverse events. Adverse events cases reported between 2004 and 2020 were studied for the involvement of colchicine in DDIs. In 66% of 787 studied reports, colchicine was identified as a concomitant drug. This indicates that the reporter did not think colchicine was the cause of the adverse events mentioned in the reports.
Could colchicine possibly play a bigger role in DDIs than currently thought?
Are there any safety concerns of colchicine use combined with strong CYP3A4 inhibitors?
And what practical guidance is needed for the safe use of colchicine in combination with other medicines?
Listen to the second episode of DDI of the Month to find out!
10 Apr 2024
Episode 1: Flucloxacillin | Ditte Iversen
In the first exciting episode of this new podcast series, Dr. Iversen and Dr. Burger will dive into DDIs with flucloxacillin, and explore the results of Dr. Iversen's research trial.
Dr. Iversen’s research group has studied the extent of induction of flucloxacillin of the CYP enzymes in healthy adults and 3D spheroid of primary human hepatocytes (PHHs). The research group performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic (Basel) cocktail study with twelve healthy adults. During the podcast, the study will be discussed in detail.
Find out the interesting results of this study!
10 Apr 2024
Episode 1: Ditte Iversen
In the first exciting episode of this new podcast series, Dr. Iversen and Dr. Burger will dive into DDIs with flucloxacillin, and explore the results of Dr. Iversen's research trial.
Dr. Iversen’s research group has studied the extent of induction of flucloxacillin of the CYP enzymes in healthy adults and 3D spheroid of primary human hepatocytes (PHHs). The research group performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic (Basel) cocktail study with twelve healthy adults. During the podcast, the study will be discussed in detail.
Find out the interesting results of this study!
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Spotify
5.0 / 5
4 ratings
Podcast Authority Score: 15 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
6
Social presence
0
YouTube
0
Engagement
60
Host of DDI of the Month Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
